.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India faces uniquely high stakes in the fight against drug-resistant infections. Specifically, C-CAMP recently hosted the second India AMR Innovation workshop in Delhi to address these challenges. Therefore, the event gathered over one hundred stakeholders to discuss collaborative strategies. Furthermore, the workshop highlighted breakthrough innovations supported by the India AMR Innovation Hub (IAIH). Consequently, the Principal Scientific Adviser launched a compendium of sixty AMR solutions. This collection features tools for diagnostics, therapeutics, and environmental monitoring. While these solutions are diverse, they all follow the One Health approach. Moreover, the IAIH now serves as the official innovation arm of India's National Action Plan (NAP) 2.0.
In addition, C-CAMP introduced the first-of-its-kind IAIH Grand Challenges. These challenges aim to incentivize solutions for critical and underfunded problems. For instance, bioremediation of antibiotic waste remains a key priority. Similarly, affordable rapid diagnostics for primary health centers require urgent attention. Consequently, the new IAIH Impact Fund will provide unified funding for biotech startups. Specifically, it supports companies from the TRL-4 stage onwards. This funding aims to improve both commercial success and public health impact. Furthermore, the workshop unveiled a new cohort of seven startups. These companies focus on detecting resistant microbes in environmental samples.
Q1: What is the primary goal of the India AMR Innovation Hub (IAIH)?
The hub aims to build a pipeline of 10–15 fully mature solutions over the next five years. These solutions will target deployment in India and other low- and middle-income countries to reduce the burden of resistance.
Q2: How does the National Action Plan (NAP) 2.0 support AMR innovation?
NAP 2.0 provides a strategic framework that integrates human, animal, and environmental health. It leverages platforms like IAIH to bridge the gap between scientific discovery and large-scale clinical implementation.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
C-CAMP hosts the 2nd India AMR Innovation Workshop, launching Grand Challenges and an Impact Fund to support startups fighting antimicrobial resistance....
6 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
